HC Wainwright Reaffirms Buy Rating for Nuvalent (NASDAQ:NUVL)

Nuvalent (NASDAQ:NUVL)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $155.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 43.20% from the company’s previous close.

NUVL has been the subject of several other reports. Wells Fargo & Company initiated coverage on shares of Nuvalent in a research note on Monday, March 30th. They issued an “overweight” rating and a $116.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $125.00 price target on shares of Nuvalent in a research note on Wednesday, April 8th. Cantor Fitzgerald increased their price target on shares of Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nuvalent currently has a consensus rating of “Moderate Buy” and an average price target of $137.25.

Nuvalent Price Performance

Shares of Nuvalent stock opened at $108.24 on Tuesday. The company has a 50-day moving average of $101.60 and a 200 day moving average of $101.06. The firm has a market cap of $8.51 billion, a price-to-earnings ratio of -18.50 and a beta of 1.31. Nuvalent has a 1 year low of $63.56 and a 1 year high of $113.01.

Insider Activity

In other news, CEO James Richard Porter sold 30,000 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $103.77, for a total transaction of $3,113,100.00. Following the sale, the chief executive officer owned 324,879 shares in the company, valued at $33,712,693.83. This represents a 8.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah Ann Miller sold 14,300 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $110.16, for a total transaction of $1,575,288.00. Following the sale, the insider owned 59,634 shares in the company, valued at approximately $6,569,281.44. The trade was a 19.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,523 shares of company stock valued at $6,290,983 in the last quarter. 10.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nuvalent

A number of institutional investors have recently made changes to their positions in NUVL. RA Capital Management L.P. purchased a new stake in shares of Nuvalent during the third quarter valued at approximately $107,794,000. Wellington Management Group LLP grew its holdings in shares of Nuvalent by 46.0% during the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after buying an additional 724,491 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Nuvalent by 13.9% during the fourth quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock valued at $527,521,000 after buying an additional 639,264 shares during the last quarter. Norges Bank purchased a new stake in shares of Nuvalent during the fourth quarter valued at approximately $57,763,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Nuvalent by 32.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock valued at $221,826,000 after buying an additional 545,542 shares during the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.